Veeda Group Acquires European
CRO – Health Data Specialists (Heads)
Expanding Global Reach & Capabilities
Ingenuity
meets passion.
A global* CRO specialized in hemato-oncology.
At Heads, scientific and technical expertise
meet hunger for excellence; every single day.
*Offices in North America, Europe, Asia-Pacific
Bringing hope to each patient
is our strongest driver
Services
Practical guidance to those beginning the challenging and rewarding journey in clinical research.
Notable Studies
A Phase 1/2 study of belantamab mafodotin administered in combination with daratumumab, lenalidomide and dexamethasone in patients with newly diagnosed MM not eligible for ASCT.
A Phase 1/2 study of belantamab mafodotin administered in combination with daratumumab, pomalidomide, and dexamethasone in relapsed/refractory MM patients treated with one line of therapy who are lenalidomide refractory.
A Phase 1/2 study of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat in naïve transplant ineligible MM patients.
A phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with NDMM as Maintenance Therapy Following ASCT
A Phase 3 pivotal study comparing daratumumab-pomalidomide-dexamethasone vs pomalidomide-dexamethasone in relapsed refractory MM patients.
A Phase 3 study of Isatuximab in combination with carfilzomib, lenalidomide and dexamethasone (KRd) vs KRd alone in treatment naïve MM patients eligible for ASCT.
A retrospective study on the management and outcomes of 4500 patients with Systemic Light Chain Amyloidosis across Europe.
A Phase 1/2 study of belantamab mafodotin in combination with lenalidomide and dexamethasone in treatment naïve MM patients not eligible for ASCT.
A Phase 2 multi-centre study of isatuximab, bortezomib, cyclophoshamide and dexamethasone, followed by isatuximab-lenalidomide maintenace in treatment naïve MM patients with severe renal impairment.
A Phase 2 multi-centre study of isatuximab in combination with pomalidomide and dexamethasone in 1st relapse lenalidomide and proteasome inhibitor exposed MM patients.
A Phase 2 multi-centre study of belantamab mafodotin in relapsed refractory AL-Amyloidosis patients.
A Phase 2 multi-centre study of daratumumab monotherapy in newly diagnosed patients with Stage 3B light chain (AL) amyloidosis.
A Phase 2 multi-centre study of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone in MM patients with extramedullary disease.
Join us to be part of a multidisciplinary team of highly skilled scientists of the forefront Clinical Research. By the way, we do also like to have fun.
